Stockscreener 앱 받기
40.02
1.32%
0.52
시장 영업 전:
40.86
0.84
+2.10%
전일 마감가:
$39.50
열려 있는:
$39.35
하루 거래량:
1.44M
Relative Volume:
1.31
시가총액:
$8.54B
수익:
$1.97B
순이익/손실:
$92.93M
주가수익비율:
98.43
EPS:
0.4066
순현금흐름:
$459.60M
1주 성능:
+1.11%
1개월 성능:
+4.22%
6개월 성능:
-12.27%
1년 성능:
-7.82%
1일 변동 폭
$39.32
$40.19
1주일 범위
$39.31
$40.27
52주 변동 폭
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
QGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
40.02 | 8.54B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts - BioSpace
Qiagen introduces QIAprep Plasmodium kit to strengthen malaria research efforts - BioSpectrum Asia
Revolutionary Malaria Test Kit: QIAGEN's New Solution Detects 5 Species with Single-Parasite Sensitivity - Stock Titan
QIAGEN N.V. Files 2024 Annual Report with SEC - TipRanks
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results - DutchNews.nl
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
QIAGEN Releases Full 2024 Annual Report: Access Complete Financial Data and Analysis - Stock Titan
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
QIAGEN NV : Jefferies reiterates its Buy rating - Marketscreener.com
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 81% - simplywall.st
Qiagen Manager Pledges Shares in Securities Lending Transaction - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
QGEN Stock Might Rise Following Partnership With Genomics England - MSN
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now? - Yahoo Finance
Digital Genome Market to Witness Remarkable Growth with QIAGEN, GenomeMe Inc., NanoString Technologies - openPR
The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses - Yahoo Finance
Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B - Medical Device Network
Qiagen at TD Cowen Conference: Strategic Growth Plans Unveiled - Investing.com
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday -March 06, 2025 at 09:14 am EST - Marketscreener.com
QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel -March 06, 2025 at 04:04 am EST - MarketScreener
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Silicon Canals
Market is not liking Qiagen's (NYSE:QGEN) earnings decline as stock retreats 4.7% this week - Simply Wall St
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
QIAGEN Announces Managerial Transactions Involving Performance Stock Units - TipRanks
QIAGEN Announces Managerial Stock Transaction - TipRanks
Qiagen Announces Managerial Stock Unit Grant - TipRanks
Qiagen Announces Managerial Stock Transactions - TipRanks
Qiagen Announces Managerial Transaction Involving Restricted Stock Units - TipRanks
Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now - MSN
Relative Strength Alert For Qiagen - Nasdaq
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
BioMérieux: complaint lodged by German company Qiagen -March 03, 2025 at 05:57 am EST - Marketscreener.com
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - sharewise
Qiagen Files Patent Infringement Complaint in Germany Against bioMerieux -March 03, 2025 at 05:02 am EST - Marketscreener.com
How QIAGEN's Patent Lawsuit Against bioMérieux Could Reshape the TB Testing Market - Stock Titan
What is Zacks Research’s Estimate for Qiagen Q1 Earnings? - Defense World
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology - Nasdaq
Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property -March 03, 2025 at 01:04 am EST - Marketscreener.com
Zacks Research Issues Negative Estimate for Qiagen Earnings - Defense World
Zacks Research Forecasts Qiagen's Q4 Earnings (NYSE:QGEN) - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
Qiagen stock touches 52-week low at $38.48 amid market shifts - Investing.com
Qiagen stock touches 52-week low at $38.48 amid market shifts By Investing.com - Investing.com South Africa
Qiagen N.V.: Some Clarity Needed Before Buying The Dip (NYSE:QGEN) - Seeking Alpha
Genetic Testing Market Future Business Opportunities - openPR
AlphaValue/Baader Europe Upgrades Qiagen to Buy, Trims PT -February 24, 2025 at 07:17 am EST - Marketscreener.com
Qiagen (NYSE:QGEN) Stock Rating Lowered by Baird R W - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 1-Year LowHere's What Happened - MarketBeat
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
1.81%
자본화:
|
볼륨(24시간):